

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/702,096	11/05/2003	Stephen D. Kuslich	C364.104.101(19478-00005) 6813		
²⁴¹¹³ PATTERSON,	7590 01/29/2007 THUENTE, SKAAR & CI	EXAMINER STEWART, ALVIN J			
4800 IDS CEN	TER				
80 SOUTH 8T	IS, MN 55402-2100	ART UNIT	PAPER NUMBER		
	·		3738		
			·	·	
SHORTENED STATUTOR	HORTENED STATUTORY PERIOD OF RESPONSE MAIL DATE		DELIVERY MODE		
3 MO	NTHS	01/29/2007	РДР		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Applicati	on No.	Applicant(s)				
Office Action Summary		10/702,0	96	KUSLICH, STEPHEN D.				
		Examine	7	Art Unit				
		Alvin J. S		3738				
Period fo	The MAILING DATE of this communic r Reply	cation appears on th	e cover sheet with the o	correspondence ad	dress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1) 又	Responsive to communication(s) filed	d on <i>06 April 2006</i> .						
, —	This action is FINAL . 2b) This action is non-final.							
, —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠ Claim(s) <u>1,2,4,8,16,17,19,23-31 and 33</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.								
6)⊠	6)⊠ Claim(s) <u>1,2,4,8,16,17,19,23-31 and 33</u> is/are rejected.							
• —	7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.								
Applicati	on Papers							
9) The specification is objected to by the Examiner.								
10)⊠ The drawing(s) filed on <u>27 September 2004</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority ι	ınder 35 U.S.C. § 119		·					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice 3) Infor	t(s) te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (P mation Disclosure Statement(s) (PTO-1449 or tr No(s)/Mail Date		4) Interview Summan Paper No(s)/Mail D 5) Notice of Informat 6) Other:	Date	O-152)			

Application/Control Number: 10/702,096

Art Unit: 3738

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 01/05/07 has been entered.

Response to Arguments

Applicant's arguments with respect to claims <u>1,2,4,8,16,17,19,23-31 and 33</u> have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 2, 4, 8, 16, 17, 19, 23-31 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Belef et al US Pub. 2002/0147496 A1 in view of Pernia et al US Patent 5,634,945.

Belef et al discloses a system comprising an injection tube (14) having a diameter similar to the partially excavated cavity (96), a volume of tissue promoting material (π 61) and an insertion device coupled to the injection tube (see π 62 & 64). Regarding claims 2 and 8, see

paragraph 65. However, Belef et al does not disclose one or more strands of the tissue promoting material.

Pernia et al disclose a biological filler comprising a plurality of strands for the purpose of replacing soft tissue which is available, cost effective and not likely to suffer rejection or complications from its use (see col. 1, lines 50-56, lines 61-66; col. 2, lines 39-42, lines 61-67; and col. 3, lines 1-20).

It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the filler of the Belef et al reference with the biocompatible filler of the Pernia et al reference in order to provide a material for use as a replacement for soft tissue which is available, cost effective, and not likely to suffer rejection or complications from its use.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alvin J. Stewart whose telephone number is 571-272-4760. The examiner can normally be reached on Monday-Friday 7:00AM-5:30PM(1 Friday B-week off).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on 571-272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/702,096 Page 4

Art Unit: 3738

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A. Struct

ALVIN J. STEWART PRIMARY EXAMINER Art Unit 3738

January 18, 2007.